[Nutrition, metabolic syndrome and morbid obesity].

Introduction: Obesity, and specifically morbid obesity (MO), is a chronic disease with serious health consequences related to the associated comorbidities and constitutes a leading risk factor for the metabolic syndrome (MS) and cardiovascular disease (CVD). In the present study we analyze the abnormalities related to MO in the plasmatic levels of nutrients (both macro and micronutrients).

Methods: We retrospectively evaluated data of 497 patients, 369 women and 128 men diagnosed of MO.

[Morbid obesity, non-alcoholic fatty liver disease, metabolic syndrome and bariatric surgery].

Objectives: The objectives of the present study are: 1) to assess protein changes in patients diagnosed with morbid obesity (MO) and non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH); 2) to assess the likely reversibility of these entities after bariatric surgery, and 3) to analyze their progression seven years after the gastric bypass.

Material And Methods: We retrospectively analyzed the data from 190 patients, 150 women (79%) and 40 men (21%) diagnosed with MO and surgically treated at our Hospital (Capella's gastric bypass). Mean age of the patients was 36.

HOMA, QUICKI and MFfm to measure insulin resistance in morbid obesity.

Background: The relationship between morbid obesity (MO) and insulin resistance (IR) has been widely demonstrated. The euglycemic-hyperglycemic clamp method for diagnosis of IR is neither practical nor cost-effective for population-based studies. However, the application of mathematical models (HOMA, QUICKI and Mf(fm) indices) can be useful.

Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis.

Background: Resistance to insulin and secondary hyperinsulinemia seem to be the putative link between morbid obesity (MO) and hypertensive disease (HD). Adipose tissue can secrete leptin and angiotensinogen, among other substances. Leptin activates the sympathetic nervous system, leading to HD.

Morbid obesity and gastric bypass surgery: biochemical profile.

Background: Morbid obesity (MO) and the pathologies associated with it constitute an important public health problem, accounting for 7% of the health expenditure in industrialized countries. An important percentage of this expense is attributed to the different biochemical tests performed in these patients, who suffer from several metabolic derangements. We evaluated the basic biochemical abnormalities in MO patients and their reversibility by weight loss after gastric bypass, to standardize the surveillance of the different metabolic abnormalities in obese patients.